2X Match My Gift
Make a tax-deductible donation and double your impact to support colorectal cancer patients, survivors, and caregivers.
What is the UGT1A1 biomarker?
The UGT1A1 gene is present in all the cells in our body. The normal UGT1A1 gene providesinstructions for making a certain enzyme called UDP glucuronosyltransferases, which helps the liver break down medications effectively.
What happens if I have the UGT1A1 biomarker?
If you have a mutation in the UGT1A1 gene, your body may not be able to process certain chemotherapy drugs.
Patients with this rare mutation have symptoms such as impaired liver function, low white cell counts, and severe diarrhea.
Your doctor will monitor you closely during your chemotherapy treatment to watch for any adverse reactions.
Who should have UGT1A1 testing?
UGT1A1 mutation testing is not routinely performed.
Patients are often tested if they have experienced severe toxicity during treatment with FOLFIRI, FOLFIRINOX, or irinotecan.
Related Topics
Other biomarkers
SidednessTop resources
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Last updated
Top five things to know about choosing sedation for your colonoscopy
You have a choice when it comes to colonoscopy sedation, and we’re here to help make that decision easier.
Last updated
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
Last updated